COLLEGEVILLE, Pa., Sept. 8 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that product shipments have begun for XYNTHA(TM) Antihemophilic Factor (Recombinant), Plasma/Albumin-Free, a new recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A, a rare, inherited blood-clotting disorder.
XYNTHA is produced using state-of-the-art manufacturing and purification processes designed to reduce the risk of viral contamination. The manufacturing process for XYNTHA is completely albumin-free from start to finish, while the purification process utilizes a unique synthetic ligand totally free of animal materials and a nanofiltration step using a 35 nanometer pore-size filter.
"We believe the state-of-the-art manufacturing and purification processes used for XYNTHA make it an exciting new therapeutic option for many patients with hemophilia A," says Robert Repella, Executive Vice-President and General Manager, Wyeth BioPharma. "The introduction of XYNTHA is the culmination of many years of research and development, and demonstrates Wyeth's continued commitment to the hemophilia community." As an added convenience for patients, Wyeth's one-of-a-kind Rapid Reconstitution (R2) Kit is provided with XYNTHA. The R2 Kit is designed to help patients save time by allowing for ease of transportation and fewer steps during rapid reconstitution.
Shipments of the Company's current recombinant factor VIII product,
ReFacto(R) Antihemophilic Factor (Recombinant) in the United States will be
discontinued as of May 31, 2009. Wyeth anticipates that many patients using
ReFacto may want to talk to their health care provider ab
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved